Tag: 400-500

In 2020,Letters in Applied Microbiology included an article by Wang, Y.; Li, X.; Wang, D.; Sun, S.; Lu, C.. Related Products of 23828-92-4. The article was titled 《In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii》. The information in the text is summarized as follows:

The aim of this study was to investigate the in vitro interactions of ambroxol hydrochloride (ABH) or amlodipine (AML) with commonly used antibacterial agents, including meropenem, imipenem-cilastatin sodium, biapenem, cefoperazone-sulbactam, polymyxin B, and tigecycline, against six carbapenem-resistant Acinetobacter baumannii (CRAB) clin. isolates. Drug interactions were interpreted using two models, i.e., the fractional inhibitory concentration index (FICI) model and the percentage of growth difference (ΔE) model. The results show that a majority of the combination groups exhibited partial synergy and additive interactions, such as the combinations of carbapenems and cefoperazone-sulbactam (SCF) with ABH or AML. While the combination of PB/AML exhibited synergistic interactions against all tested isolates, and PB/ABH exhibited synergistic interactions against two isolates. The FICI and ΔE model correlated very well for the combinations of PBABH and PB/AML against AB2. The combinations of TGC with ABH or AML mainly exhibited additive and indifferent interactions. There were no antagonistic interactions observed in any of the combinations. In conclusion, this study revealed that the non-antibacterial agents ABH or AML can work synergistically or partial synergistically with antibacterial agents against CRAB. This finding is crucial for overcoming the carbapenem resistance of A. baumannii. In addition to this study using trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride, there are many other studies that have used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Related Products of 23828-92-4) was used in this study.

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.Related Products of 23828-92-4 Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Okunlola, Adenike; Odeniyi, Michael Ayodele; Arhewoh, Matthew Ikhuoria published an article in Progress in Biomaterials. The title of the article was 《Microsphere formulations of ambroxol hydrochloride: influence of Okra (Abelmoschus esculentus) mucilage as a sustained release polymer》.Name: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The author mentioned the following in the article:

Ambroxol hydrochloride (AH), a secretion-releasing expectorant, is a good candidate for sustained delivery. Mucilages are biodegradable, inexpensive carriers in microsphere formulations. The study aimed to prepare microspheres of AH using Okra mucilage obtained from pods of Abelmoschus esculentus combined with sodium alginate at various polymer/drug ratios. Okra mucilage was characterized for morphol., swelling, viscosity and flow properties. AH microspheres were prepared by ionic emulsification method and characterized using size, entrapment efficiency, swelling index and dissolution time (t50). A full 2 by 3 factorial exptl. design using three factors (Okra mucilage/alginate ratio X1; drug/polymer ratio X2; and polymer concentration X3), each at two levels, was used to determine the effects of formulation variables on the responses. Optimized formulations of AH microspheres had sizes ranging from 250.91 ± 16.22 to 462.10 ± 23.85μm; swelling index 1.35 ± 0.05 and 3.20 ± 0.03 and entrapment 55.70 ± 3.55-94.11 ± 4.50%. The microspheres exhibited sustained release of AH over a prolonged period as revealed by the dissolution time (t50) 2.85 ± 1.03-7.50 ± 0.96 h. Drug release kinetics generally followed zero order, implying that the process is constant and independent of the initial concentration of drug. Polymer concentration had the highest influence on microsphere size, entrapment efficiency and dissolution time while Okra/alginate ratio had the highest influence on swelling. Okra mucilage was a suitable polymer that could serve as an alternative to synthetic polymers in sustaining the release of ambroxol hydrochloride. After reading the article, we found that the author used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Name: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Name: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Manjunatha, N. K.; Kumar, S. Madan; Swamy, M. T.; Siddaraju, B. P.; Lokanath, N. K. published an article in Chemical Data Collections. The title of the article was 《Solid state and Computational studies of Ambroxol hydrochloride drug》.Application In Synthesis of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The author mentioned the following in the article:

The title compound Ambroxol hydrochloride salt or 4-[(2-amino-3, 5-dibromophenyl) Me amino] cyclohexan-1-olhydrochloride (A) have been crystallized, characterized using FT-IR and confirmed by single crystal X-ray diffraction method. In addition, the intercontacts in the crystal structure are analyzed using Hirshfeld surfaces computational method. The A crystallizes in a monoclinic crystal system (space group C2/c) with cell parameters a = 25.1946(14) Å, b = 15.5139(9) Å, c = 8.1636(5) Å, β = 94.664(6)°, V = 3180.3(3) Å3 and Z = 8. An intermol. interaction of the type O-H… O, N-H… Cl, C-H… Br, C-H… Cg and C-Br… Cg stabilizes the crystal structure. The intercontacts in the crystal structures are visualized using 2D finger print plots. The electrostatic potential surfaces and topol. surfaces (shape index (S) and curvedness (C)) are plotted over the Hirshfeld surfaces to identify the potentials (pos. and neg.) and mol. surface topol., resp. Intercontacts are evaluated for the propensity of forming contacts in the crystal packing by enrichment ration (E) values. The presence of C-Br… Br-C intermol. interactions are confirmed using E values and is categorized as Type I halogen…halogen intermol. interactions. The experimental process involved the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Application In Synthesis of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Application In Synthesis of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

In 2019,Latin American Journal of Pharmacy included an article by Dong, Hui; Weng, Yibing; Zhen, Genshen. Category: alcohols-buliding-blocks. The article was titled 《Clinical efficacy of atomizing inhalation of ambroxol hydrochloride in treatment of chronic bronchitis in elderly patients》. The information in the text is summarized as follows:

This study aimed to investigate the clin. efficacy of atomizing inhalation of ambroxol hydrochloride in treatment of chronic bronchitis in elderly patients. Four hundred elderly patients with chronic bronchitis were randomly divided into control and observation group, which received conventional treatment and atomizing inhalation of ambroxol hydrochloride based on conventional treatment, resp. After treatment, compared with control group, in observation group the disappearance time of clin. symptoms was decreased (P < 0.05), the total effective rate was increased (P < 0.01), the lung function, life quality and daily activity ability were improved (P < 0.05), the serum IL-2 level was increased (P < 0.05), and the serum IL-6 and TNF-α levels were decreased (P < 0.05). There was no significant difference of adverse reaction between two groups (P > 0.05). Atomizing inhalation of ambroxol hydrochloride can quickly and effectively alleviate the clin. symptoms of chronic bronchitis in elderly patients. The experimental part of the paper was very detailed, including the reaction process of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Category: alcohols-buliding-blocks)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.Category: alcohols-buliding-blocks Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

In 2019,Frontiers in Pharmacology included an article by Bouscary, Alexandra; Quessada, Cyril; Mosbach, Althea; Callizot, Noelle; Spedding, Michael; Loeffler, Jean-Philippe; Henriques, Alexandre. Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride. The article was titled 《Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis》. The information in the text is summarized as follows:

Amyotrophic lateral sclerosis (ALS) is a multifactorial and fatal neurodegenerative disease. Growing evidence connects sphingolipid metabolism to the pathophysiol. of ALS. In particular, levels of ceramides, glucosylceramides, and gangliosides are dysregulated in the central nervous system and at the neuromuscular junctions of both animal models and patients. Glucosylceramide is the main precursor of complex glycosphingolipids that is degraded by lysosomal (GBA1) or non-lysosomal (GBA2) glucocerebrosidase. Here, we report that GBA2, but not GBA1, activity is markedly increased in the spinal cord, of SOD1G86R mice, an animal model of familial ALS, even before disease onset. We therefore investigated the effects of ambroxol hydrochloride, a known GBA2 inhibitor, in SOD1G86R mice. A presymptomatic administration of ambroxol hydrochloride, in the drinking water, delayed disease onset, protecting neuromuscular junctions, and the number of functional spinal motor neurons. When administered at disease onset, ambroxol hydrochloride delayed motor function decline, protected neuromuscular junctions, and extended overall survival of the SOD1G86R mice. In addition, ambroxol hydrochloride improved motor recovery and muscle re-innervation after transient sciatic nerve injury in non-transgenic mice and promoted axonal elongation in an in vitro model of motor unit. Our study suggests that ambroxol hydrochloride promotes and protects motor units and improves axonal plasticity, and that this generic compound is a promising drug candidate for ALS. In the experiment, the researchers used many compounds, for example, trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《Efficacy and safety of ambroxol hydrochloride in the treatment of secretory otitis media: a systematic review and meta-analysis》 was published in Annals of Translational Medicine in 2022. These research results belong to Zhou, Xufeng; Jin, Xiulin; Yang, Linhong; Wei, Xiaoli. Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The article mentions the following:

Secretory otitis media is a very common nonsuppurative inflammatory disease in otorhinolaryngol. Ambroxol hydrochloride helps to improve ciliary movement in the ear canal and promote the dissolution and discharge of secretions. However, its effect still lacks systematic evaluation. We conducted a meta-anal. of clin. studies to systematically evaluate the application effect of ambroxol hydrochloride. A computer-based search of the Chinese Biomedical Database (CBM), China National Knowledge Infrastructure (CNKI), PubMed, and Web of Science databases was conducted using the keywords “”Ambroxol hydrochloride”” & “”secretory otitis media””. Randomized controlled trials published after 2015 were selected and then screened and analyzed using RevMan 5.4 software. Ten studies involving a total of 998 patients were included. Meta-anal. showed that adding ambroxol hydrochloride to the original glucocorticoid treatment improved therapeutic efficacy [odds ratio (OR) = 4.95, 95% confidence interval (CI): 3.27, 7.50, P<0.00001], reduced tympanic pressure after treatment [mean difference (MD) = -19.04, 95% CI: -22.72, -15.36, P<0.00001], and increased the pure tone threshold (MD =6.37, 95% CI: 5.36, 7.37, P<0.00001), without increasing adverse reactions (OR = 0.51, 95% CI: 0.14, 1.85, P=0.30). On the basis of the original treatment of secretory otitis media, adding ambroxol hydrochloride treatment improved the therapeutic effect, reduced tympanic pressure after treatment, and improved the pure tone threshold (hearing), without increasing adverse reactions. The experimental process involved the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《Box-Behnken Experimental Design Aided Optimization of Stability Indicating HPTLC-Based Assay Method: Application in Pharmaceutical Dosage form Containing Model Drugs-Roxithromycin and Ambroxol Hydrochloride》 was published in Analytical Chemistry Letters in 2019. These research results belong to Patel, Rashmin B.; Patel, Mrunali R.; Patel, Nilay M.. Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The article mentions the following:

The objective of this study was to apply Design of Experiment (DoE) concept for development of stability indicating high-performance thin-layer chromatog. (HPTLC) method for assay of model drugs (Roxithromycin (ROXTM) and Ambroxol hydrochloride (AMBRX)) in marketed tablet formulations followed by validation of developed HPTLC method as per ICHQ2(R1). Box-Behnken exptl. design was applied to optimize chromatog. conditions and their effects on retardation factor (Rf) value. The developed HPTLC method was validated for specificity, linearity, accuracy, precision, and robustness. The ROXTM (Rf 0.42) and AMBRX (Rf 0.75) were well separated (Rs 2.06) from each other and from their resp. degradation products on HPTLC plate using optimized chromatog. conditions. The developed method was successfully validated and statistical anal. proved that the method is sensitive, specific (peak purity > 0.9999 for both ROXTM and AMBRX), accurate (98.59-101.14% and 99.96-101.76%, ROXTM and AMBRX, resp.) and precise (% RSD >1.0 for both ROXTM and AMBRX). The developed HPTLC method have advantages over reported methods in being robust and able to determine the model drugs and degradation products with sensitivity, selectivity and short anal. time using simple mobile phase. In addition to this study using trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride, there are many other studies that have used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride) was used in this study.

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

In 2021,Chemical & Pharmaceutical Bulletin included an article by Ijitsu, Shin; Hoashi, Yohei; Hori, Koji; Okimoto, Kazuto; Kai, Toshiya; Yoshida, Miyako; Uchida, Takahiro. Product Details of 23828-92-4. The article was titled 《Preparation of novel functional drug particles embedded in a gelling-swelling layer (PEGS) for taste masking and subsequent rapid drug release》. The information in the text is summarized as follows:

The purpose of this research was to develop novel functional drug particles embedded in a gelling-swelling layer (PEGS) which are capable of achieving both taste-masking of unpalatable drugs and rapid drug elution. The functional particles had a three-layer structure consisting of a core drug layer, a gelling-swelling layer and an outer water-penetration control layer containing a water-insoluble polymer. The concept of formulation design was as follows: when water reaches the gelling-swelling layer, pulverized fine gelling-swelling particles gellate and swell from water absorption to form a rigid layer, thereby preventing drug release. After a defined lag time, the increased volume of the gelling-swelling layer breaks down the outer water-penetration control layer, leading to rapid drug release. In order to adapt this system for use in orally disintegrating tablets, PEGS were prepared at a size of about 250μm using a fine particle-coating method. Ambroxol hydrochloride was used as a model drug for bitterness and the effects of different gelling-swelling agents and water-insoluble polymers on drug release characteristics from PEGS were examined In in vitro dissolution tests, it was shown that the drug dissolution rate from PEGS could be suppressed to about 5% after 2 min and increased to more than 85% after 30 min by adjusting the composition and thickness of the outer layer. The PEGS expanded about 1.5-fold and the outer layer was ruptured after 5 min in water. The experimental process involved the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Product Details of 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.Product Details of 23828-92-4 Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Holmes, Sean T.; Vojvodin, Cameron S.; Schurko, Robert W. published their research in Journal of Physical Chemistry A on December 10 ,2020. The article was titled 《Dispersion-Corrected DFT Methods for Applications in Nuclear Magnetic Resonance Crystallography》.Electric Literature of C13H19Br2ClN2O The article contains the following contents:

Nuclear elec. field gradient (EFG) tensor parameters depend strongly on electronic structures, making their calculation from first principles an excellent metric for the prediction, refinement, and optimization of crystal structures. Here, we use plane-wave d. functional theory (DFT) calculations of EFG tensors in organic solids to optimize the Grimme (D2) and Tkatchenko-Scheffler (TS) at.-pairwise force field dispersion corrections. Refinements using these new force field correction methods result in better representations of true crystal structures, as gauged by calculations of 177 14N, 17O, and 35Cl EFG tensors from 95 materials. The most striking result is the degree by which calculations of 35Cl EFG tensors of chloride ions match with experiment, due to the ability of these new methods to properly locate the positions of hydrogen atoms participating in H···Cl- hydrogen bonds. These refined structures also feature at. coordinates that are more similar to those of neutron diffraction structures than those obtained from calculations that do not employ the optimized force fields. Addnl., we assess the quality of these new energy-minimization protocols for the prediction of 15N magnetic shielding tensors and unit cell volumes, which complement the larger anal. using EFG tensors, since these quantities have different phys. origins. It is hoped that these results will be useful in future NMR crystallog. studies and will be of great interest to a wide variety of researchers, in fields including NMR spectroscopy, computational chem., crystallog., pharmaceutical sciences, and crystal engineering. In the experiment, the researchers used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Electric Literature of C13H19Br2ClN2O)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.Electric Literature of C13H19Br2ClN2O Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

COA of Formula: C13H19Br2ClN2OOn September 30, 2022 ,《Facile approaches for determination of Bromhexine Hydrochloride and its active metabolite Ambroxol Hydrochloride using Eosin Y》 was published in Annales Pharmaceutiques Francaises. The article was written by El-Sayed, A.; Elmansi, H.; Shalan, S.; Eid, M.. The article contains the following contents:

New validated Spectroscopic methods were developed to assay Bromhexine Hydrochloride and its active metabolite Ambroxol Hydrochloride sep. in pure form and pharmaceutical formulations. The spectrophotometric assay (method I) shows complex formation between each of the drugs and Eosin Y at 540 nm at pH 3.6 and 3.4 mL of 4 x 10-4M Eosin for Bromhexine and Ambroxol. The Spectrofluorimetric assay (method II) depends on quenching eosin native fluorescence by the studied drugs, which measured at 540 nm after excitation at 302 nm. The spectrophotometric absorbance-concentration plot is rectilinear over the ranges (1.0-5.0) and (1.0-10.0) μg/mL for bromhexine and ambroxol with LOD of 0.31 and 0.14μg/mL and LOQ of 0.94 and 0.42μg/mL for the two drugs resp. The fluorometric-concentration plot is linear along the range (1.0-5.0) μg/mL and (1-10) μg/mL for the two drugs resp. with LOD of 0.13μg/mL and 0.22μg/mL and LOQ of 0.4μg/mL and 0.65μg/mL for the two drugs, resp. Developed assays have been validated in agreement with ICH recommendations and they were used in the anal. of com. drug formulations containing the two mucolytic drugs and the results were matching with those obtained by the comparison method.De nouvelles methodes spectroscopiques validees ont etedeveloppes pour doser le chlorhydrate de bromhexine et son metabolite actif, le chlorhydrate d’Ambroxol, sous forme pure et dans des formulations pharmaceutiques. Le dosage spectrophotometrique (methode I) montre la formation d’un complexe entre chacun des medicaments et l’eosine Y a540 nm a pH 3,6 et 3,4 mL d’eosine 4 x 10-4M pour la bromhexine et l’ambroxol. Le dosage spectrofluorimetrique (methode II) depend de l’extinction de la fluorescence native de l’eosine par les medicaments etudies, qui a ete mesuree a 540 nm apres excitation a 302 nm. Le trace spectrophotometrique. Le trace spectrophotometrique absorbance-concentration est lineaire sur les plages (1,0-5,0) et (1,0-10,0) μg/mL pour la bromhexine et l’ambroxol avec LOD de 0,31 et 0,14μg/mL et LOQ de 0,94 et 0,42μg/mL pour les deux medicaments respectivement. Le trace de la concentration fluorometrique est lineaire le long de la plage (1,0-5,0) μg/mL et (1-10) μg/mL pour les deux medicaments respectivement avec LOD de 0,13μg/mL et 0,22μg/mL et LOQ de 0,4μg/ mL et 0,65μg/mL pour les deux medicaments, respectivement. Les tests developpes ont ete valides en accord avec les recommandations de l’ICH et ils ont ete utilizes dans l’analyze des formulations de medicaments commerciaux contenant les deux medicaments mucolytiques et les resultats correspondaient a ceux obtenus par la methode de comparaison. In the experimental materials used by the author, we found trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4COA of Formula: C13H19Br2ClN2O)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.COA of Formula: C13H19Br2ClN2O Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts